TaiGen Biopharmaceuticals Holdings Limited - Laporan Laba Rugi (TTM)

TaiGen Biopharmaceuticals Holdings Limited
TW ˙ TPEX
NT$ 14.10 ↓ -0.05 (-0.35%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi TaiGen Biopharmaceuticals Holdings Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 22 23 66 1,303 1,301 1,295 1,258 16 33 36 32 129 119 123 127 149 149 151 151 41
Change (%) 5.42 182.86 1,867.13 -0.17 -0.50 -2.82 -98.71 103.30 9.67 -10.81 299.51 -7.61 3.24 3.49 17.28 -0.47 1.28 0.54 -73.14
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 7 4 14 12 12 13 3 3 4 4 6 9 11 11 13 13 14 16 18 19
Change (%) -45.24 250.35 -18.51 1.19 9.10 -77.38 3.37 19.80 4.86 62.07 42.08 28.36 3.67 9.98 6.62 2.82 16.87 13.63 5.10
% of Revenue 33.17 17.23 21.34 0.88 0.90 0.98 0.23 18.30 10.79 10.31 18.74 6.66 9.26 9.30 9.88 8.98 9.28 10.71 12.10 47.35
Gross Operating Profit 15 19 52 1,292 1,289 1,282 1,255 13 29 32 26 120 108 112 115 136 135 135 133 21
Change (%) 30.57 168.81 2,378.78 -0.18 -0.59 -2.08 -98.94 122.00 10.26 -19.19 358.87 -10.18 3.20 2.83 18.45 -0.79 -0.32 -1.03 -83.91
% of Revenue 66.83 82.77 78.66 99.12 99.10 99.02 99.77 81.70 89.21 89.69 81.26 93.34 90.74 90.70 90.12 91.02 90.72 89.29 87.90 52.65
SG&A 59 77 81 101 103 99 99 89 78 73 74 72 83 99 100 106 105 91 83 75
Change (%) 30.52 4.31 24.71 2.04 -3.41 0.32 -10.53 -12.54 -6.59 1.92 -2.70 14.90 19.48 1.51 5.31 -0.33 -14.08 -8.28 -10.28
% of Revenue 266.45 329.89 121.65 7.71 7.88 7.65 7.90 547.23 235.42 200.50 229.12 55.80 69.40 80.32 78.78 70.74 70.84 60.10 54.83 183.17
R&D 241 249 260 297 274 283 293 284 262 238 213 181 201 187 194 189 183 166 155 138
Change (%) 3.62 4.10 14.23 -7.59 3.35 3.43 -3.23 -7.48 -9.46 -10.18 -14.94 10.84 -6.80 3.56 -2.62 -3.18 -9.28 -6.84 -11.12
% of Revenue 1,083.55 1,064.98 391.95 22.76 21.07 21.88 23.29 1,744.88 794.12 655.60 660.22 140.58 168.66 152.26 152.36 126.51 123.06 110.23 102.14 338.02
OpEx 307 331 354 409 388 395 395 375 344 314 293 262 295 298 307 308 302 273 256 231
Change (%) 7.63 7.16 15.30 -4.98 1.74 0.05 -5.02 -8.46 -8.66 -6.52 -10.67 12.53 0.97 3.12 0.35 -1.94 -9.76 -6.11 -9.68
% of Revenue 1,383.18 1,412.10 534.95 31.36 29.85 30.52 31.42 2,310.41 1,040.33 866.41 908.08 203.04 247.32 241.88 241.02 206.23 203.19 181.05 169.08 568.54
Operating Income -285 -307 -288 895 913 899 863 -359 -311 -278 -261 -133 -176 -175 -180 -159 -153 -122 -105 -191
Change (%) 7.80 -6.24 -410.46 2.02 -1.45 -4.08 -141.63 -13.52 -10.61 -5.96 -49.06 32.09 -0.57 2.86 -11.65 -3.32 -20.45 -14.31 82.18
% of Revenue -1,283.18 -1,312.10 -434.95 68.64 70.15 69.48 68.58 -2,210.41 -940.33 -766.41 -808.08 -103.04 -147.32 -141.88 -141.02 -106.23 -103.19 -81.05 -69.08 -468.54
Interest Expense -1 -1 -0 -0 -0 -0 -0 -1 -1 -1 -1 -1 -1 -1 -1 -2 -2 -1 -1 -2
Change (%) -8.94 -19.47 -19.42 -24.10 -17.57 68.44 42.82 30.15 11.78 -10.19 -11.21 33.19 25.36 20.14 16.76 -5.39 -5.63 -3.58 16.90
% of Revenue -2.97 -2.57 -0.73 -0.03 -0.02 -0.02 -0.03 -3.61 -2.31 -2.36 -2.37 -0.53 -0.76 -0.92 -1.07 -1.07 -1.01 -0.95 -0.91 -3.95
Net Income -474 -405 -376 827 785 776 786 -417 -264 -237 -254 -142 -161 137 181 235 172 -39 -55 -242
Change (%) -14.57 -7.05 -319.80 -5.10 -1.18 1.35 -153.03 -36.56 -10.32 7.25 -44.23 13.64 -184.82 32.34 29.96 -26.97 -122.47 42.73 339.75
% of Revenue -2,132.87 -1,728.37 -567.99 63.46 60.33 59.92 62.48 -2,565.54 -800.57 -654.61 -787.17 -109.89 -135.17 111.04 142.00 157.35 115.46 -25.61 -36.36 -595.28

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista